A new trial for patients with Waldenström’s macroglobulinaemia (PembroWM) opened to recruitment in September at the following hospitals: Derriford, Churchill, Royal Bournemouth and UCLH. The trial is run by the CR UK & UCL Cancer Trials Centre and is supported by Merck, Sharp and Dohme Ltd.
PembroWM is a single arm, phase II trial that will recruit patients who have previously been treated for Waldenström’s macroglobulinaemia whose disease has not responded or returned. These patients will receive a combination of two immunotherapy drugs, Rituximab and Pembrolizumab, which stimulate the body’s immune system to fight cancer cells. The main aim of the trial is to investigate whether the combination of Rituximab and Pembrolizumab is a safe and effective drug combination for this disease.
The trial is a national study which requires 42 patients to take part. It will open in 8 UK sites. PembroWM is due to complete recruitment in 2021.